Jun
2026
Shanghai New International Expo Center
Visit us
stand E2D16a, Pharma Ingredients

Chongqing Sintaho Pharmaceutical Co., Ltd.

Exhibitor at CPHI & PMEC China 2026
About Us

In 2016, Chongqing Sintaho Pharmaceutical Co., Ltd. (Sintaho, a legal person sole proprietorship) with 300+ employees, was jointly invested and set up by Chongqing Taihao Pharmaceutical Co., Ltd. (Taihao, founded in 2004) and an American New Drug Company in Chongqing International Biological City, China.Sintaho specializes in the field of chemical synthesis and has established 3 core ranges of APIs on 2 platforms: GLP-1+ APIs on the polypeptide platform, high-potency APIs and XDC compounds on the small molecule platform. Benefiting from the existing platform and our team's experience with multiple international certifications (FDA, PMDA, ANSM, TGA, etc.), we also provide cost- and quality-competitive APIs to generic drug companies, and one-stop C(D)MO services spanning from chemical structure modification to long-term LCM to new drug companies.With the mission of "produce high quality pharmaceuticals to improve human health", Sintaho is committed to becoming a dependable API supplier/service provider in the global pharmaceutical supply chain.

Read more Show less
Products
Show more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2023
  • Certificates:
    4
  • Employees:
    250 - 499
Company types
CMO/CDMO
Contract Service
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
View company profile
Contact info
  • 008602388961278
  • #600, Liuqing Rd., Maliuzui Town, Banan District, 401319, Chongqing, China
Show contact info Hide contact info
Event information
CPHI & PMEC China 2026
  • 16 Jun 2026 - 18 Jun 2026
  • Shanghai New International Expo Center
  • Visit us at stand E2D16a, Pharma Ingredients

Products Featured at CPHI & PMEC China 2026

  • Eribulin Mesylate

    Product Eribulin Mesylate

    Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
  • Deruxtecan

    Product Deruxtecan

    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
  • Exatecan Mesylate

    Product Exatecan Mesylate

    Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.
  • MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH

    Product MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH

    MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • Paclitaxel

    Product Paclitaxel

    Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.